Display options
Cite
Stępień PM, Reczko K, Wieczorek A, et al. Severe intrahepatic cholestasis and liver failure after stanozolol usage - case report and review of the literature. Clin Exp Hepatol. 2015;1(1):30-33doi: 10.5114/ceh.2015.51376.
Stępień, P. M., Reczko, K., Wieczorek, A., Zarębska-Michaluk, D., Pabjan, P., Król, T., & Kryczka, W. (2015). Severe intrahepatic cholestasis and liver failure after stanozolol usage - case report and review of the literature. Clinical and experimental hepatology, 1(1), 30-33. https://doi.org/10.5114/ceh.2015.51376
Stępień, Piotr M, et al. "Severe intrahepatic cholestasis and liver failure after stanozolol usage - case report and review of the literature." Clinical and experimental hepatology vol. 1,1 (2015): 30-33. doi: https://doi.org/10.5114/ceh.2015.51376
Stępień PM, Reczko K, Wieczorek A, Zarębska-Michaluk D, Pabjan P, Król T, Kryczka W. Severe intrahepatic cholestasis and liver failure after stanozolol usage - case report and review of the literature. Clin Exp Hepatol. 2015 May;1(1):30-33. doi: 10.5114/ceh.2015.51376. Epub 2015 Apr 30. PMID: 28856252; PMCID: PMC5421162.
Copy Download .nbib Format: NLM
Share it on

Clin Exp Hepatol. 2015 May;1(1):30-33. doi: 10.5114/ceh.2015.51376. Epub 2015 Apr 30.

Severe intrahepatic cholestasis and liver failure after stanozolol usage - case report and review of the literature.

Clinical and experimental hepatology

Piotr M Stępień, Katarzyna Reczko, Anna Wieczorek, Dorota Zarębska-Michaluk, Paweł Pabjan, Teodora Król, Wiesław Kryczka

Affiliations

  1. Clinic of Infectious Diseases, Regional Polyclinic Hospital, Kielce, Poland.
  2. Department of Cell Biology and Electron Microscopy, Institute of Biology, Jan Kochanowski University, Kielce, Poland.
  3. Department of Internal Diseases, Cardiology and Internal Medicine Nursing, Institute of Nursing and Maternity, Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland.

PMID: 28856252 PMCID: PMC5421162 DOI: 10.5114/ceh.2015.51376

Abstract

Stanozolol is a 17α-alkylated synthetic anabolic steroid used illegally by bodybuilders. We present a 19-year-old man who was taking 50 mg of stanozolol intramuscularly, every other day for 2 months, to improve muscle mass. On admission, his bilirubin concentration was 44.34 mg/dl. The serum levels of liver enzymes were normal, with only alanine aminotransferase being slightly elevated. Liver biopsy revealed toxic hepatitis of minor grade with periportal fibrosis and intrahepatic cholestasis. Medical treatment of the patient was conservative. Despite the therapy the patient's general condition deteriorated - bilirubin level increased to 56.64 mg/dl, and INR rose to 1.7. Then we decided to administer low doses of hydrocortisone. As a result of the treatment, bilirubin concentration was 14.61 mg/dl after 2 weeks. Finally all hepatic enzymes returned to normal values 5 months after stanozolol was discontinued. This treatment appears to be safe and leads to a more rapid reduction of bilirubin.

Keywords: anabolic steroids; cholestasis; hydrocortisone; liver failure; stanozolol

Conflict of interest statement

Authors report no conflict of interest.

References

  1. Rev Esp Enferm Dig. 2006 Mar;98(3):219-20 - PubMed
  2. World J Hepatol. 2013 Mar 27;5(3):133-6 - PubMed
  3. J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):336-43 - PubMed
  4. Semin Liver Dis. 1987 Aug;7(3):230-6 - PubMed
  5. Br J Sports Med. 2005 May;39(5):e27 - PubMed
  6. Liver Int. 2011 Mar;31(3):348-53 - PubMed
  7. Scand J Med Sci Sports. 2011 Dec;21(6):e247-59 - PubMed
  8. Curr Opin Pharmacol. 2004 Dec;4(6):614-20 - PubMed
  9. Br J Sports Med. 2007 Jul;41(7):462-3 - PubMed
  10. Wien Med Wochenschr. 1993;143(14-15):399-400 - PubMed
  11. J Clin Gastroenterol. 2002 Oct;35(4):350-2 - PubMed
  12. J Clin Gastroenterol. 1988 Aug;10(4):467-8 - PubMed
  13. Hepatology. 2005 Aug;42(2):481-9 - PubMed
  14. CMAJ. 1994 Sep 15;151(6):791-3 - PubMed
  15. Digestion. 2011;84(1):54-9 - PubMed
  16. Dtsch Med Wochenschr. 1999 Sep 10;124(36):1029-32 - PubMed
  17. J Hepatol. 1997;26 Suppl 1:1-4 - PubMed
  18. Clin Gastroenterol Hepatol. 2007 Jul;5(7):809-12 - PubMed

Publication Types